Weekly Research Analysts’ Ratings Updates for Progyny (PGNY)

Several analysts have recently updated their ratings and price targets for Progyny (NASDAQ: PGNY):

• 1/8/2026 – Progyny had its price target raised by analysts at KeyCorp from $30.00 to $32.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Progyny was upgraded by analysts at Truist Financial Corporation from a “hold” rating to a “buy” rating. They now have a $34.00 price target on the stock.
• 1/3/2026 – Progyny was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/1/2026 – Progyny was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 12/29/2025 – Progyny had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Progyny had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Progyny was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/15/2025 – Progyny had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Progyny is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $29.00 price target on the stock.
• 12/8/2025 – Progyny is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $29.00 price target on the stock.
• 11/17/2025 – Progyny had its price target raised by analysts at Canaccord Genuity Group Inc. from $23.00 to $26.00. They now have a “hold” rating on the stock.
• 11/11/2025 – Progyny was upgraded by analysts at KeyCorp from a “sector weight” rating to an “overweight” rating. They now have a $30.00 price target on the stock.
• 11/11/2025 – Progyny had its price target raised by analysts at JPMorgan Chase & Co. from $25.00 to $26.00. They now have a “neutral” rating on the stock.

Insider Activity at Progyny

In other Progyny news, CEO Peter Anevski bought 79,500 shares of Progyny stock in a transaction that occurred on Thursday, November 13th. The shares were acquired at an average price of $24.29 per share, for a total transaction of $1,931,055.00. Following the acquisition, the chief executive officer owned 680,251 shares of the company’s stock, valued at $16,523,296.79. The trade was a 13.23% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Mark S. Livingston sold 21,303 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $25.50, for a total value of $543,226.50. Following the completion of the sale, the chief financial officer owned 48,358 shares of the company’s stock, valued at approximately $1,233,129. This represents a 30.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 22,046 shares of company stock valued at $561,691. 9.40% of the stock is owned by insiders.

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.